Chi‐an Chen - Gynecology

Author Information

Chi-An Chen is a distinguished researcher affiliated with the Department of Obstetrics and Gynecology at National Taiwan University Hospital, Taipei 100, Taiwan. With a comprehensive background in gynecologic oncology, Chi-An Chen has contributed significantly to the understanding and advancement of treatments for various gynecologic malignancies.

Research Contributions

Chi-An Chen has authored numerous impactful papers in the field of gynecology. In 2021 alone, Chi-An Chen published significant research on topics ranging from the risks of secondary malignancies in endometrial cancer survivors to the evaluation of modern adjuvant radiotherapy in women with stage IB endometrial cancer. Earlier works include studies on the use of PET/MRI in cervical cancer, the efficacy of pyrotinib in HER2-positive advanced breast cancer, and the role of immune checkpoint blockades in enhancing cancer therapy. The research contributions of Chi-An Chen span multiple high-impact topics, reflecting a deep commitment to improving patient outcomes in gynecologic oncology.

Aliases

Chi-An Chen is also known by the aliases Chi-an Chen and Chi‐an Chen in various publications.

Publication and Citation Metrics

Metric	Value
Citation Count	6472
H-Index	35
Paper Count	162

Publications:

Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A population‐based analysis

DOI: 10.1002/cam4.3861

Year: 2021

Devising Hyperthermia Dose of NIR-Irradiated Cs0.33WO3 Nanoparticles for HepG2 Hepatic Cancer Cells

DOI: 10.1186/s11671-021-03565-4

Year: 2021

A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes

DOI: 10.3390/biomedicines9101384

Year: 2021

Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer

DOI: 10.3390/cancers13061386

Year: 2021

PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival

DOI: 10.1002/jmri.27311

Year: 2020

Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: Results from a retrospective study in real-world setting

DOI: 10.1016/s0959-8049(20)30680-8

Year: 2020

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization

DOI: 10.3390/cancers11091400

Year: 2019

CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells.

DOI: 10.1530/ERC-18-0300

Year: 2019

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

DOI: 10.1186/s40425-019-0744-4

Year: 2019

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies

DOI: 10.3389/fphar.2019.00426

Year: 2019

What Are the Treatment Options for BPH?

Are there any financial aids or scholarships available for aspiring Gynecologists?

What is Natural Family Planning?

Why Pursue a Subspecialty?

What are the Risks and Complications of Parenteral Nutrition?

How Can Healthcare Providers Overcome Language Barriers?

Why is Export Important in Gynecology?

What Happens After the Examination?

What is Interdisciplinary Research in Gynecology?

What resources are available for sexual health education?

Partnered Content Networks

Relevant Topics